Home › Therapeutic areas › Hematology › Polycythemia Vera
Polycythemia Vera (7 companies)
Companies with an active program in Polycythemia Vera.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 1 | Approved | $1.76B | 7 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 1 | Phase 2 | $151M | 6 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $6.55B | 29 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 1 | Phase 1 | $287M | 3 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 2 | Approved | $8.62B | 12 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
No companies match.